Show simple item record

dc.contributor.authorYavuz, B.en_US
dc.contributor.authorAta, N.en_US
dc.contributor.authorOto, E.en_US
dc.contributor.authorKatircioglu-Öztürk, D.en_US
dc.contributor.authorAytemir, K.en_US
dc.contributor.authorEvranos, B.en_US
dc.contributor.authorKoselerli, R.en_US
dc.contributor.authorErtugay, E.en_US
dc.contributor.authorBurkan, A.en_US
dc.contributor.authorErtugay, E.en_US
dc.contributor.authorGale, C. P.en_US
dc.contributor.authorCamm, A. J.en_US
dc.contributor.authorOto, A.en_US
dc.date.accessioned2018-04-12T11:04:22Z
dc.date.available2018-04-12T11:04:22Z
dc.date.issued2017en_US
dc.identifier.issn1099-5129
dc.identifier.urihttp://hdl.handle.net/11693/37156
dc.description.abstractAims: Although atrial fibrillation (AF) is increasingly common in developed countries, there is limited information regarding its demographics, co-morbidities, treatments and outcomes in the developing countries. We present the profile of the TuRkish Atrial Fibrillation (TRAF) cohort which provides real-life data about prevalence, incidence, comorbidities, treatment, healthcare utilization and outcomes associated with AF. Methods and results: The TRAF cohort was extracted from MEDULA, a health insurance database linking hospitals, general practitioners, pharmacies and outpatient clinics for almost 100% of the inhabitants of the country. The cohort includes 507 136 individuals with AF between 2008 and 2012 aged >18 years who survived the first 30 days following diagnosis. Of 507 136 subjects, there were 423 109 (83.4%) with non-valvular AF and 84 027 (16.6%) with valvular AF. The prevalence was 0.80% in non-valvular AF and 0.28% in valvular AF; in 2012 the incidence of non-valvular AF (0.17%) was higher than valvular AF (0.04%). All-cause mortality was 19.19% (97 368) and 11.47% (58 161) at 1-year after diagnosis of AF. There were 35 707 (7.04%) ischaemic stroke/TIA/thromboembolism at baseline and 34 871 (6.87%) during follow-up; 11 472 (2.26%) major haemorrhages at baseline and 10 183 (2.01%) during followup, and 44 116 (8.69%) hospitalizations during the follow-up. Conclusion: The TRAF cohort is the first population-based, whole-country cohort of AF epidemiology, quality of care and outcomes. It provides a unique opportunity to study the patterns, causes and impact of treatments on the incidence and outcomes of AF in a developing country. Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017.en_US
dc.language.isoEnglishen_US
dc.source.titleEuropaceen_US
dc.relation.isversionofhttp://dx.doi.org/10.1093/europace/euw385en_US
dc.subjectAtrial fibrillationen_US
dc.subjectCHA2DS2Vascen_US
dc.subjectIncidence of atrial fibrillationen_US
dc.subjectPopulation-based cohorten_US
dc.subjectAtrial fibrillationen_US
dc.subjectTransient ischemic attacken_US
dc.subjectThromboembolismen_US
dc.subjectQuality of careen_US
dc.subjectHemorrhageen_US
dc.subjectIschemic strokeen_US
dc.subjectEpidemiologyen_US
dc.subjectAmbulatory care facilitiesen_US
dc.subjectDemographyen_US
dc.subjectDeveloped countriesen_US
dc.subjectDeveloping countriesen_US
dc.subjectFollow-upen_US
dc.subjectHealth insuranceen_US
dc.subjectPharmaciesen_US
dc.subjectPhysiciansen_US
dc.subjectDiagnosisen_US
dc.subjectMorbidityen_US
dc.subjectMortalityen_US
dc.subjectHealth care useen_US
dc.subjectTurkishen_US
dc.titleDemographics, treatment and outcomes of atrial fibrillation in a developing country: the population-based TuRkish Atrial Fibrillation (TRAF) cohorten_US
dc.typeArticleen_US
dc.departmentCyberparken_US
dc.citation.spage734en_US
dc.citation.epage740en_US
dc.citation.volumeNumber19en_US
dc.citation.issueNumber5en_US
dc.identifier.doi10.1093/europace/euw385en_US
dc.publisherOxford University Pressen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record